Psychiatrist Warns: 7-OH Kratom Binds to Opioid Receptors at 13x Morphine's Potency, Treatment Access Lags Behind Bans

Why it matters

As states rush to ban 7-OH, addiction psychiatrists are warning that bans without parallel treatment expansion will leave patients with a severe opioid-like dependence and nowhere to turn — a pattern already seen in the fentanyl crisis.

The big picture

7-hydroxymitragynine (7-OH) has rapidly proliferated from specialty kratom retailers to mainstream vape shops over the past two years, reaching far more users than traditional kratom leaf. Addiction medicine specialists are now seeing patients whose 7-OH dependence rivals opioid use disorder in severity, but who may not be identified or treated through standard opioid pathways. Psychiatric comorbidity further complicates treatment.

Key findings

• 7-OH binds to mu-opioid receptors at approximately 13 times the potency of morphine, per Dr. Jason Kirby, CMO of Recovery Centers of America
• Abrupt cessation produces a profound opioid-like withdrawal syndrome
• 7-OH has spread rapidly across vape shops in states where it remains legal over the past two years
• One patient took out a second mortgage and spent the proceeds within six months to sustain a 7-OH habit
• Approximately 50% of SUD patients have undiagnosed or undertreated psychiatric illness; 70% have a trauma history
• Clinicians are urged to screen for 7-OH use and connect patients to pharmacological withdrawal management

What they say

"I actually had a patient who took out a second mortgage on their house, and ended up spending that within 6 months, just on kratom," said Dr. Jason Kirby, CMO of Recovery Centers of America.

Bottom line

States banning 7-OH without expanding opioid treatment access risk leaving a wave of severely dependent patients without clinical support.